Ipca Laboratories (IPCALAB) Stock Overview
An integrated pharmaceutical company, manufactures and markets formulations and active pharmaceutical ingredients (APIs) for various therapeutic segments in India, Europe, Africa, the Americas, Asia, the Commonwealth of Independent States, and Australasia. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 3/6 |
| Past Performance | 4/6 |
| Financial Health | 5/6 |
| Dividends | 3/6 |
Rewards
Risk Analysis
No risks detected for IPCALAB from our risk checks.
IPCALAB Community Fair Values
Create NarrativeSee what 6 others think this stock is worth. Follow their fair value or set your own to get alerts.
The Market Is Sleeping on This Parkinson's Biotech - And I Think That's a Mistake
Gain Therapeutics: The Under-the-Radar Biotech With Big Parkinson’s Potential Key Takeaways Gain Therapeutics (GANX) is developing GT-02287 – an oral, first-in-class, potentially disease-modifying treatment for Parkinson’s disease targeting the GCase enzyme pathway. Parkinson’s disease represents a $4 billion U.S. market with zero approved disease-modifying therapies.Read more
Ipca Laboratories Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹1,456.20 |
| 52 Week High | ₹1,624.00 |
| 52 Week Low | ₹1,251.60 |
| Beta | 0.15 |
| 1 Month Change | -6.70% |
| 3 Month Change | -7.54% |
| 1 Year Change | 9.41% |
| 3 Year Change | 77.61% |
| 5 Year Change | 35.97% |
| Change since IPO | 3,732.11% |
Recent News & Updates
Recent updates
Here's What Analysts Are Forecasting For Ipca Laboratories Limited (NSE:IPCALAB) After Its Third-Quarter Results
Feb 18
Does Ipca Laboratories (NSE:IPCALAB) Have A Healthy Balance Sheet?
Feb 12Ipca Laboratories Limited's (NSE:IPCALAB) Earnings Haven't Escaped The Attention Of Investors
Jan 21Is Now The Time To Put Ipca Laboratories (NSE:IPCALAB) On Your Watchlist?
Dec 09Shareholders Should Be Pleased With Ipca Laboratories Limited's (NSE:IPCALAB) Price
Oct 19If EPS Growth Is Important To You, Ipca Laboratories (NSE:IPCALAB) Presents An Opportunity
Sep 05The Ipca Laboratories Limited (NSE:IPCALAB) First-Quarter Results Are Out And Analysts Have Published New Forecasts
Aug 15Ipca Laboratories (NSE:IPCALAB) Will Pay A Dividend Of ₹2.00
Jul 08Ipca Laboratories' (NSE:IPCALAB) Dividend Will Be ₹2.00
Jun 24Ipca Laboratories Limited Just Missed Earnings - But Analysts Have Updated Their Models
Jun 01Ipca Laboratories Limited (NSE:IPCALAB) Not Lagging Market On Growth Or Pricing
May 22Results: Ipca Laboratories Limited Exceeded Expectations And The Consensus Has Updated Its Estimates
Feb 16Ipca Laboratories (NSE:IPCALAB) Seems To Use Debt Rather Sparingly
Jan 10Why We're Not Concerned About Ipca Laboratories Limited's (NSE:IPCALAB) Share Price
Dec 20
Synergies With Unichem Laboratories And US Market Re-entry Will Boost Future Earnings
Strong domestic formulation growth and market share improvement position Ipca Laboratories for increased revenues and earnings.Ipca Laboratories (NSE:IPCALAB) Is Paying Out A Dividend Of ₹2.00
Nov 17Earnings Tell The Story For Ipca Laboratories Limited (NSE:IPCALAB)
Sep 10Ipca Laboratories' (NSE:IPCALAB) Solid Earnings Have Been Accounted For Conservatively
Jun 07Ipca Laboratories Limited (NSE:IPCALAB) Not Lagging Market On Growth Or Pricing
May 24Investors Interested In Ipca Laboratories Limited's (NSE:IPCALAB) Earnings
Feb 07Here's Why Ipca Laboratories (NSE:IPCALAB) Can Manage Its Debt Responsibly
Jan 09Is Ipca Laboratories (NSE:IPCALAB) A Risky Investment?
Aug 20Ipca Laboratories (NSE:IPCALAB) Has A Pretty Healthy Balance Sheet
Feb 28Here's Why Ipca Laboratories (NSE:IPCALAB) Can Manage Its Debt Responsibly
Sep 20Estimating The Intrinsic Value Of Ipca Laboratories Limited (NSE:IPCALAB)
Aug 31Is Ipca Laboratories (NSE:IPCALAB) A Risky Investment?
Jun 22Calculating The Fair Value Of Ipca Laboratories Limited (NSE:IPCALAB)
May 28Shareholder Returns
| IPCALAB | IN Pharmaceuticals | IN Market | |
|---|---|---|---|
| 7D | -2.2% | 2.7% | 6.9% |
| 1Y | 9.4% | 5.1% | 7.0% |
Return vs Industry: IPCALAB exceeded the Indian Pharmaceuticals industry which returned 5.1% over the past year.
Return vs Market: IPCALAB exceeded the Indian Market which returned 7% over the past year.
Price Volatility
| IPCALAB volatility | |
|---|---|
| IPCALAB Average Weekly Movement | 3.8% |
| Pharmaceuticals Industry Average Movement | 6.5% |
| Market Average Movement | 7.3% |
| 10% most volatile stocks in IN Market | 10.3% |
| 10% least volatile stocks in IN Market | 4.7% |
Stable Share Price: IPCALAB has not had significant price volatility in the past 3 months compared to the Indian market.
Volatility Over Time: IPCALAB's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1949 | 16,778 | Pranay Godha | www.ipca.com |
Ipca Laboratories Limited, an integrated pharmaceutical company, manufactures and markets formulations and active pharmaceutical ingredients (APIs) for various therapeutic segments in India, Europe, Africa, the Americas, Asia, the Commonwealth of Independent States, and Australasia. The company offers APIs in anti-hypertensive, anti-malarial, diuretic, DMARD, anti-hypertensive, and anthelmintic therapeutic areas. It also provides generic and branded formulations in various therapeutic segments, including allergy, anti-neoplastic/cancer drugs, anti-arthritic, anti-epileptic, anti-hypertensive, cardiology, diabetes, dermatology, diabetology, emollients/protectives, fever, gastroenterology, helminthics, hepatoprotectives, immunosuppressant, infectious diseases, malaria, neurology, neuropathic pain, and NSAIDs, as well as nutraceuticals, ophthalmology, oral anti diabetes drug, orthopedics, probiotics, psychiatry, respiratory, rheumatology, and urology.
Ipca Laboratories Limited Fundamentals Summary
| IPCALAB fundamental statistics | |
|---|---|
| Market cap | ₹369.44b |
| Earnings (TTM) | ₹9.10b |
| Revenue (TTM) | ₹95.06b |
Is IPCALAB overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| IPCALAB income statement (TTM) | |
|---|---|
| Revenue | ₹95.06b |
| Cost of Revenue | ₹31.42b |
| Gross Profit | ₹63.64b |
| Other Expenses | ₹54.54b |
| Earnings | ₹9.10b |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | 35.86 |
| Gross Margin | 66.94% |
| Net Profit Margin | 9.57% |
| Debt/Equity Ratio | 14.4% |
How did IPCALAB perform over the long term?
See historical performance and comparisonDividends
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/04/11 04:14 |
| End of Day Share Price | 2026/04/10 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Ipca Laboratories Limited is covered by 43 analysts. 17 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Aditya Khemka | Ambit Capital |
| Sanjeev Chiniwar | Anand Rathi Shares and Stock Brokers Limited |
| null null | Anand Rathi Shares and Stock Brokers Limited |